citalopram + selegiline

Citalopram + selegiline is a combination of two small molecule drugs used primarily in the management of major depression, particularly in patients with Parkinson's disease. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic activity by inhibiting the sodium-dependent serotonin transporter, thereby increasing serotonin levels in the brain. Selegiline is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor that prevents dopamine breakdown and prolongs its effects in the central nervous system. The combination has been studied at low doses (citalopram 20 mg daily and selegiline 5–10 mg daily), showing efficacy and safety for treating major depression in Parkinson’s disease without significant pharmacodynamic or pharmacokinetic interactions at these doses[1][2][3]. However, caution is warranted due to potential risk of serotonin syndrome if higher doses or other serotonergic agents are involved.